HC Wainwright Comments on Journey Medical Q1 Earnings

Journey Medical Corporation (NASDAQ:DERM) – HC Wainwright issued their Q1 2026 earnings per share (EPS) estimates for shares of Journey Medical in a note issued to investors on Wednesday, March 25th. HC Wainwright analyst B. Folkes expects that the company will post earnings per share of ($0.05) for the quarter. HC Wainwright currently has a “Buy” rating and a $13.00 target price on the stock. The consensus estimate for Journey Medical’s current full-year earnings is ($1.02) per share. HC Wainwright also issued estimates for Journey Medical’s Q2 2026 earnings at ($0.04) EPS, Q3 2026 earnings at $0.07 EPS, Q4 2026 earnings at $0.17 EPS, FY2026 earnings at $0.16 EPS, FY2027 earnings at $1.16 EPS, FY2028 earnings at $1.76 EPS, FY2029 earnings at $1.90 EPS and FY2030 earnings at $2.01 EPS.

Journey Medical (NASDAQ:DERM) last released its earnings results on Wednesday, March 25th. The company reported ($0.04) earnings per share (EPS) for the quarter, topping analysts’ consensus estimates of ($0.06) by $0.02. The business had revenue of $16.08 million during the quarter, compared to analyst estimates of $18.86 million. Journey Medical had a negative net margin of 18.48% and a negative return on equity of 51.42%.

Separately, Weiss Ratings reissued a “sell (d-)” rating on shares of Journey Medical in a research note on Wednesday, January 21st. Three research analysts have rated the stock with a Buy rating, one has assigned a Hold rating and one has assigned a Sell rating to the company. According to data from MarketBeat, Journey Medical currently has a consensus rating of “Hold” and a consensus target price of $13.00.

Journey Medical Stock Performance

DERM opened at $4.57 on Friday. The firm’s 50-day moving average price is $7.93 and its 200 day moving average price is $7.79. Journey Medical has a twelve month low of $4.51 and a twelve month high of $9.56. The firm has a market capitalization of $152.00 million, a PE ratio of -9.72 and a beta of 0.81. The company has a current ratio of 1.42, a quick ratio of 1.12 and a debt-to-equity ratio of 0.75.

Institutional Inflows and Outflows

Several large investors have recently bought and sold shares of DERM. Invesco Ltd. purchased a new position in Journey Medical during the 4th quarter valued at about $127,000. XTX Topco Ltd purchased a new position in shares of Journey Medical during the 4th quarter worth approximately $126,000. Ikarian Capital LLC acquired a new position in shares of Journey Medical during the 4th quarter worth approximately $1,939,000. Occudo Quantitative Strategies LP lifted its stake in Journey Medical by 22.3% in the 4th quarter. Occudo Quantitative Strategies LP now owns 18,913 shares of the company’s stock valued at $146,000 after buying an additional 3,443 shares in the last quarter. Finally, Opaleye Management Inc. lifted its stake in Journey Medical by 0.4% in the 4th quarter. Opaleye Management Inc. now owns 975,000 shares of the company’s stock valued at $7,517,000 after buying an additional 3,936 shares in the last quarter. Hedge funds and other institutional investors own 7.25% of the company’s stock.

Key Journey Medical News

Here are the key news stories impacting Journey Medical this week:

• Positive Sentiment: Q4 EPS beat street expectations — Journey reported EPS of ($0.04) vs. consensus ($0.06), which investors often view as a sign management is managing costs and edging toward profitability. Earnings Press Release
• Positive Sentiment: Management highlighted robust prescription demand for Emrosi and outlined a path to EBITDA growth and expanded Emrosi coverage — messaging that supports a profitability story if execution continues. Seeking Alpha: Emrosi & EBITDA Growth
• Positive Sentiment: HC Wainwright reaffirmed a Buy rating and a $13 price target (large upside vs. current levels), and published multi‑year EPS ramps that imply meaningful recovery/profitability over 2026–2030 — a catalyst for momentum investors. HC Wainwright Buy, $13 PT
• Neutral Sentiment: Analyst estimates were revised slightly downward in some out years (FY2026–2029) even as the Buy rating and $13 target remain; this moderates upside timing but keeps a bullish thesis intact. TipRanks Coverage
• Negative Sentiment: Revenue missed estimates — $16.08M vs. consensus ~$18.86M — and the company still shows negative margins and negative ROE, underscoring execution risk on the revenue side. Zacks: Q4 Metrics vs Estimates
• Negative Sentiment: Shares are trading near 12‑month lows and below key short‑term moving averages amid above‑average volume, indicating selling pressure and short‑term technical weakness. MarketBeat: DERM Stock Page

About Journey Medical

Journey Medical Corp, headquartered in Fairfield, New Jersey, is a commercial dermatology company focused on acquiring, developing and marketing prescription dermatology products in the United States. Since its incorporation in 2019, the company has built a portfolio of both branded and generic topical therapies designed to address a range of skin conditions, including acne, atopic dermatitis, fungal infections and inflammatory lesions.

The company’s product lineup features antibiotic/anti-inflammatory combinations and corticosteroid-based formulations delivered through proprietary gel, cream and foam vehicles.